Novel therapies in genitourinary cancer: an update
2008
Update on Novel Therapies for Genitourinary Cancer
publication
Evidence: moderate
Author Information
Author(s): David Chu, Shenhong Wu
Primary Institution: Stony Brook University Medical Center
Hypothesis
The study explores the effectiveness of new targeted therapies for renal cell carcinoma (RCC) and other genitourinary malignancies.
Conclusion
New targeted therapies for RCC have shown promise in improving patient outcomes compared to traditional treatments.
Supporting Evidence
- The introduction of targeted therapies has significantly changed the treatment landscape for RCC.
- Survival rates for RCC have improved due to earlier detection and new treatment options.
- Targeted therapies have shown better safety profiles compared to traditional chemotherapy.
Takeaway
Doctors are finding new medicines that help people with kidney cancer live longer and feel better than older treatments.
Methodology
The article reviews recent advancements in targeted therapies for RCC and summarizes findings from clinical trials presented at the 2008 ASCO meeting.
Limitations
The review does not provide new experimental data but summarizes existing studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website